Fig. 8: Pharmacological Inhibition of PRMT3 Decreases GBM growth.
From: PRMT3 drives glioblastoma progression by enhancing HIF1A and glycolytic metabolism
A Growth of U251 and U87 cells treated with SGC707 (10 μM) at the indicated times after treatment initiation. n = 3 independent assays. B Growth inhibition of GSC28 and GSC262 cells treated with SGC707 (10 μM) at the indicated times after treatment initiation. n = 3 independent assays. C Growth of HEB and HMO6 normal brain cells treated with SGC707 (10 μM) at the indicated times after treatment initiation. n = 3 independent assays. D, E ECAR of GSC262 cells after treatment with SGC707 for 72 h (D) and quantification (E). n = 5 independent assays. F Photomicrographs of tumors formed in the flanks of nude mice injected with GSC262 cells that were treated with DMSO or SGC707. G Volumes of tumors formed in the flanks of nude mice injected with GSC262 cells that were treated with DMSO or SGC707. Arrow: treatment starting date. n = 5 or 6 animals/group. H Weights of tumors formed in the flanks of nude mice injected with GSC262 cells that were treated with DMSO or SGC707. n = 5 or 6 animals/group. I Photomicrographs of tumors formed in the flanks of nude mice injected with GSC20 cells that were treated with DMSO or SGC707. J Weights of tumors formed in the flanks of nude mice injected with GSC20 cells that were treated with DMSO or SGC707. n = 5 animals/group. Data are presented as means ± SEM; *p < 0.05, **p < 0.01; ***p < 0.001; two-tailed unpaired Student t-test. N.S., not significant.
